Trevi Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $89.40 Mil.
During the past 12 months, Trevi Therapeutics's average Total Assets Growth Rate was 156.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 44.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 8.40% per year.
During the past 7 years, Trevi Therapeutics's highest 3-Year average Total Assets Growth Rate was 117.20%. The lowest was -20.90%. And the median was 21.10%.
Total Assets is connected with ROA %. Trevi Therapeutics's annualizedROA % for the quarter that ended in Dec. 2023 was -33.77%. Total Assets is also linked to Revenue through Asset Turnover. Trevi Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
Trevi Therapeutics Total Assets Historical Data
The historical data trend for Trevi Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Trevi Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trevi Therapeutics (NAS:TRVI) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Trevi Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Trevi Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Trevi Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Trevi Therapeutics (Trevi Therapeutics) Business Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRVI has been successfully added to your 